VERQUVO DIN 02537052
Health Canada record
| Active ingredient(s) | VERICIGUAT 5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C01DX22 VERICIGUAT |
| Original market date | 19-Sep-2023 |
| Current status date | 19-Sep-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VERICIGUAT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02537044 | VERQUVO | BAYER INC | Tablet | VERICIGUAT 2.5 MG | Marketed |
| 02537060 | VERQUVO | BAYER INC | Tablet | VERICIGUAT 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30582 | 2023-04-28 | New Drug Submission (NDS) |
International API supply for VERICIGUAT
7 active FDA Drug Master Files.
Request a quote for VERQUVO